Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2025-04-03 Declaration of Voting R…
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva SE Shareholding Declaration - March 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "VALNEVA Declaration of shares and voting rights March 31, 2025" and explicitly details the total number of shares, total voting rights (including and excluding suspended rights), and notes changes related to double voting rights granted over a specific period in March 2025. This content directly relates to the structure of voting rights attached to the company's capital, which aligns precisely with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is a declaration of rights rather than the final result of a vote, the specific focus on the total voting rights count makes DVA the most appropriate classification over general regulatory filings (RNS) or director dealings (DIRS).
2025-04-03 English
Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Déclaration d'actions et de droits de vote" (Declaration of shares and voting rights) and is dated March 31, 2025, declared on April 3, 2025. It explicitly details the total number of shares, the total number of voting rights (gross and net), and notes variations related to voting rights (e.g., 'Passage en droit de vote double'). This content directly corresponds to the official reporting of voting rights and share capital structure, which aligns precisely with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific declaration about voting rights.
2025-04-03 French
Regulatory Filings 2025
Regulatory Filings
2025-04-03 English
6-K
Regulatory Filings
2025-04-01 English
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
Regulatory Filings Classification · 96% confidence The document is a press release dated April 1, 2025, announcing that the European Commission granted marketing authorization for Valneva's Chikungunya vaccine (IXCHIQ®) for adolescents aged 12 and above. This type of announcement, detailing a significant regulatory milestone (marketing authorization/label extension) and providing key context, financial/partnership updates (CEPI grant, SII agreement), and forward-looking statements, is characteristic of an Earnings Release (ER) or a general press release regarding corporate/product news. Since it focuses on a major regulatory achievement and product update rather than just preliminary financial figures (ER) or a full annual review (10-K), it fits best under the general category for significant corporate announcements that aren't strictly financial reports or management changes. However, given the options, this is a primary announcement of a major corporate/product development. It is not a Call Transcript (CT), Annual Report (10-K), or Interim Report (IR). It is a press release announcing a regulatory event. While 'RNS' (Regulatory Filings) is a fallback, 'ER' (Earnings Release) often encompasses major operational/regulatory news releases, especially when they are time-sensitive and market-moving. In many databases, major product/regulatory news releases are grouped with ERs or treated as a specific type of press release. Given the structure and content (announcement of a major regulatory event with quotes and context), it strongly resembles an Earnings Release format, even if it's not tied to a quarterly period. If we strictly follow the definitions, it's a major announcement. Since it's not a formal financial report (10-K, IR) or a proxy/governance document, and it's a direct announcement of a significant event, 'ER' is the closest fit for a major corporate news announcement, although 'RNS' is also plausible as a general regulatory announcement. I will classify it as 'ER' because it functions as the primary news release for a significant corporate event, which often overlaps with ER releases in structure.
2025-04-01 English
Valneva : le vaccin contre le chikungunya, IXCHIQ®, désormais autorisé chez les adolescents dans l'UE
Regulatory Filings Classification · 100% confidence The document is a press release dated April 1, 2025, announcing that the European Commission granted marketing authorization for Valneva's chikungunya vaccine (IXCHIQ®) for adolescents aged 12 and over in the EU. It details regulatory achievements, clinical trial results, and partnerships (CEPI, SII). This type of announcement, focusing on a specific regulatory milestone (marketing authorization/approval) and providing key context and results, aligns best with an Earnings Release (ER) or a general announcement. Since it is not a full annual report (10-K), a quarterly report (IR), or a transcript (CT), and it is a formal announcement of a significant business/regulatory event, it fits the 'Earnings Release' category (ER) which often encompasses major operational and regulatory news releases, or potentially 'Regulatory Filings' (RNS) if it were less detailed. Given the structure and content (major news announcement with supporting details), ER is the most appropriate fit among the specific options, as it functions as a major corporate update, even if not strictly tied to quarterly financials. However, since it is a press release announcing a regulatory approval, and not explicitly an 'Earnings Release' (which usually focuses on financial performance metrics), it is a strong candidate for a general Regulatory Filing (RNS) or a specific announcement type. Reviewing the definitions, it is not a DVA, DIV, CAP, or MANG. It is a press release announcing a regulatory success. In many databases, major regulatory news releases that aren't financial results are classified as RNS. Given the context of a major regulatory approval announcement, RNS (Regulatory Filings - general regulatory announcements and fallback) is a very strong fit, as it is a formal communication to the market about a regulatory event. Since it is a detailed press release and not just a short notice of publication, it is more than just an RPA. I will classify it as RNS as it is a significant regulatory announcement that doesn't fit the other specific categories like ER (which usually implies financial results).
2025-04-01 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.